The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Jun. 07, 2021
Applicants:

Toyama Prefectural University, Toyama, JP;

Teika Pharmaceutical Co., Ltd., Toyama, JP;

National Institute of Advanced Industrial Science and Technology, Tokyo, JP;

Inventors:

Yoshinori Nagai, Toyama, JP;

Naoki Okamoto, Toyama, JP;

Shigeto Fujishita, Toyama, JP;

Takatsugu Hirokawa, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/10 (2006.01); A61P 37/06 (2006.01); C07C 33/38 (2006.01); C07C 43/178 (2006.01); C07C 43/23 (2006.01); C07C 57/48 (2006.01); C07C 69/757 (2006.01); C07C 219/22 (2006.01); C07C 219/30 (2006.01); C07C 311/04 (2006.01); C07D 205/04 (2006.01); C07D 211/38 (2006.01); C07D 295/096 (2006.01); C07D 295/185 (2006.01); C07D 307/94 (2006.01);
U.S. Cl.
CPC ...
C07D 405/10 (2013.01); A61P 37/06 (2018.01); C07C 33/38 (2013.01); C07C 43/1788 (2013.01); C07C 43/23 (2013.01); C07C 57/48 (2013.01); C07C 69/757 (2013.01); C07C 219/22 (2013.01); C07C 219/30 (2013.01); C07C 311/04 (2013.01); C07D 205/04 (2013.01); C07D 211/38 (2013.01); C07D 295/096 (2013.01); C07D 295/185 (2013.01); C07D 307/94 (2013.01);
Abstract

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.


Find Patent Forward Citations

Loading…